Stock IOLCP IOL CHEMICALS AND PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings IOL Chemicals and Pharmaceuticals Limited

Equities

IOLCP

INE485C01011

Delayed Bombay S.E.
Other stock markets
 12:18:24 2024-07-03 am EDT 		5-day change 1st Jan Change
430.2 INR +0.68% Intraday chart for IOL Chemicals and Pharmaceuticals Limited +6.38% -7.12%
Jul. 02 IOL Chemicals Gets Chinese Regulator's Nod to Export Fenofibrate to China; Shares Up 7% MT
May. 16 Transcript : IOL Chemicals and Pharmaceuticals Limited, Q4 2024 Earnings Call, May 16, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
IOL CHEMICALS AND PHARMACEUTICALS LIMITED Stock IOL Chemicals and Pharmaceuticals Limited
-7.12% 288M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
A+
NOVARTIS AG Stock Novartis AG
+13.66% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IOLCP Stock
  4. Ratings IOL Chemicals and Pharmaceuticals Limited